FDA to review Pfizer's tofacitinib

FDA accepted for review an NDA from Pfizer Inc. (NYSE:PFE) for tofacitinib to treat moderate to severe active rheumatoid arthritis (RA). The PDUFA date is in August. The oral pan-Janus kinase (JAK) in...